{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:32:55Z","timestamp":1778963575157,"version":"3.51.4"},"reference-count":34,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":1523,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Despite evidence of the effectiveness of injectable opioid treatment compared with oral methadone for chronic heroin addiction, the additional cost of injectable treatment is considerable, and cost-effectiveness uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To compare the cost-effectiveness of supervised injectable heroin and injectable methadone with optimised oral methadone for chronic refractory heroin addiction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Multisite, open-label, randomised controlled trial. Outcomes were assessed in terms of quality-adjusted life-years (QALYs). Economic perspective included health, social services and criminal justice resources.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Intervention costs over 26 weeks were significantly higher for injectable heroin (mean \u00a38995 v. \u00a34674 injectable methadone and \u00a32596 oral methadone;<jats:italic>P<\/jats:italic>&lt;0.0001). Costs overall were highest for oral methadone (mean \u00a315805 v. \u00a313410 injectable heroin and \u00a310945 injectable methadone;<jats:italic>P<\/jats:italic>=n.s.) due to higher costs of criminal activity. In cost-effectiveness analysis, oral methadone was dominated by injectable heroin and injectable methadone (more expensive and less effective). At willingness to pay of \u00a330 000 per QALY, there is a higher probability of injectable methadone being more cost-effective (80%) than injectable heroin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Injectable opioid treatments are more cost-effective than optimised oral methadone for chronic refractory heroin addiction. The choice between supervised injectable heroin and injectable methadone is less clear. There is currently evidence to suggest superior effectiveness of injectable heroin but at a cost that policy makers may find unacceptable. Future research should consider the use of decision analytic techniques to model expected costs and benefits of the treatments over the longer term.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.bp.112.111583","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T03:58:56Z","timestamp":1379044736000},"page":"341-349","source":"Crossref","is-referenced-by-count":76,"title":["Cost-effectiveness of injectable opioid treatment<i>v<\/i>. oral methadone for chronic heroin addiction"],"prefix":"10.1192","volume":"203","author":[{"given":"Sarah","family":"Byford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Metrebian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teodora","family":"Groshkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikki","family":"Charles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Strang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000053563_ref16","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"S0007125000053563_ref10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.951116314.x"},{"key":"S0007125000053563_ref18","volume-title":"NHS Reference Costs 2008.","year":"2008"},{"key":"S0007125000053563_ref32","volume-title":"A New Approach to Fighting Crime.","year":"2011"},{"key":"S0007125000053563_ref2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923060-00002"},{"key":"S0007125000053563_ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01225.x"},{"key":"S0007125000053563_ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7150.13"},{"key":"S0007125000053563_ref30","doi-asserted-by":"publisher","DOI":"10.1002\/1099-176X(200003)3:1<11::AID-MHP66>3.0.CO;2-0"},{"key":"S0007125000053563_ref3","volume-title":"New Heroin-Assisted Treatment: Recent Evidence and Current Practices of Supervised Injectable Heroin Treatment in Europe and Beyond.","author":"Strang","year":"2011"},{"key":"S0007125000053563_ref27","volume-title":"Guide to the Methods of Technology Appraisal","year":"2008"},{"key":"S0007125000053563_ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39308.560069.BE"},{"key":"S0007125000053563_ref5","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.026112"},{"key":"S0007125000053563_ref11","volume-title":"Measuring Different Aspects of Problem Drug Use: Methodological Developments","author":"Gordon","year":"2006"},{"key":"S0007125000053563_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(94)00677-7"},{"key":"S0007125000053563_ref23","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P"},{"key":"S0007125000053563_ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00296.x"},{"key":"S0007125000053563_ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810635"},{"key":"S0007125000053563_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60349-2"},{"key":"S0007125000053563_ref8","volume-title":"British National Formulary 55 (March).","year":"2008"},{"key":"S0007125000053563_ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-3-28"},{"key":"S0007125000053563_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6"},{"key":"S0007125000053563_ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hec.901"},{"key":"S0007125000053563_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.08.012"},{"key":"S0007125000053563_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.015"},{"key":"S0007125000053563_ref19","volume-title":"The Unit Costs of Health and Social Care 2008.","author":"Curtis","year":"2008"},{"key":"S0007125000053563_ref20","volume-title":"The Economic and Social Costs of Crime against Individuals and Households 2003\/04.","author":"Dubourg","year":"2005"},{"key":"S0007125000053563_ref22","volume-title":"Prison Service Annual Report and Accounts 2008","year":"2009"},{"key":"S0007125000053563_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/0167-6296(93)90005-Y"},{"key":"S0007125000053563_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(98)00039-3"},{"key":"S0007125000053563_ref26","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.2.106"},{"key":"S0007125000053563_ref28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2001.43040.x"},{"key":"S0007125000053563_ref21","volume-title":"MPS Ready Reckoner.","year":"2000"},{"key":"S0007125000053563_ref31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7503.1297"},{"key":"S0007125000053563_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/cbm.724"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000053563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:33:45Z","timestamp":1715981625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000053563\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0007125000053563"],"URL":"https:\/\/doi.org\/10.1192\/bjp.bp.112.111583","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}